全盆底悬吊术治疗盆腔脏器脱垂的术后并发症研究进展

近10年，针对盆腔脏器脱垂(POP)的手术治疗，已从20世纪初期的阴道折叠术，发展为20世纪80年代的各类改良术式，并不断应用于临床。目前，临床治疗POP应用较多的为经阴道植入网片(TVM)全盆底重建术，又称为全盆底悬吊术，以及腹腔镜下子宫/阴道-骶骨固定术。尽管对POP施行全盆底悬吊术时，TVM的应用已经被列入成品化时代，但由于全盆底悬吊术后出现的相关并发症较多，因此TVM开始被临床限制使用。2008及2011年，美国食品药品管理局(FDA)就TVM引发的并发症进行了2次安全警示。笔者拟就目前对全盆底悬吊术治疗POP的术后并发症的研究进展进行综述如下。

Research progress of postoperative complications in treatment of pelvic organ prolapse by whole pelvic floor ventrofixation

Over the past 10 years, surgical treatment of pelvic organ prolapse (POP) has developed from placation of vagina in the early 20th century to various advanced surgical vagina repairs in the 1980s. The most common clinical treatment of POP so far is transvaginal mesh (TVM) total pelvic floor reconstruction surgery for repair of POP which also called as whole pelvic floor ventrofixation, and laparoscopic sacro-colpopexy. Although application of TVM has been in the era of finished products during whole pelvic floor ventrofixation was performed, there were more related complications after whole pelvic floor ventrofixation, and this limited its use in clinical. In 2008 and 2001, the United State Food and Drug Administration (FDA) carried out safety warnings two times about related complications caused by TVM. This paper focuses on the research progress of related complications caused by TVM after whole pelvic floor ventrofixation for repair of POP.